ZLAB Quote, Financials, Valuation and Earnings

NovoCure has a net margin of -40.75% compared to Zai Lab's net margin of -19.71%. Zai Lab's return on equity of -35.53% beat NovoCure's return on equity of -40.75%.

Zai Lab has a consensus price target of $52.39, signalling upside risk potential of 95.93%. On the other hand NovoCure has an analysts' consensus of -- which suggests that it could grow by 13.53%. Given that Zai Lab has higher upside potential than NovoCure, analysts believe Zai Lab is more attractive than NovoCure.

Zai Lab has a beta of 0.989, which suggesting that the stock is 1.054% less volatile than S&P 500. In comparison NovoCure has a beta of 0.748, suggesting its less volatile than the S&P 500 by 25.16%.

Zai Lab has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovoCure offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zai Lab pays -- of its earnings as a dividend. NovoCure pays out -- of its earnings as a dividend.

Zai Lab quarterly revenues are $102.3M, which are smaller than NovoCure quarterly revenues of $155.1M. Zai Lab's net income of -$41.7M is lower than NovoCure's net income of -$30.6M. Notably, Zai Lab's price-to-earnings ratio is -- while NovoCure's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zai Lab is 7.33x versus 5.74x for NovoCure. Usually stocks with elevated PS ratios are considered overvalued.

Dr Reddy's Laboratories has a net margin of -40.75% compared to Zai Lab's net margin of 15.66%. Zai Lab's return on equity of -35.53% beat Dr Reddy's Laboratories's return on equity of 19.35%.

Zai Lab has a consensus price target of $52.39, signalling upside risk potential of 95.93%. On the other hand Dr Reddy's Laboratories has an analysts' consensus of $14.11 which suggests that it could grow by 0.85%. Given that Zai Lab has higher upside potential than Dr Reddy's Laboratories, analysts believe Zai Lab is more attractive than Dr Reddy's Laboratories.

Zai Lab has a beta of 0.989, which suggesting that the stock is 1.054% less volatile than S&P 500. In comparison Dr Reddy's Laboratories has a beta of 0.533, suggesting its less volatile than the S&P 500 by 46.687%.

Zai Lab has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dr Reddy's Laboratories offers a yield of 0.62% to investors and pays a quarterly dividend of $0.10 per share. Zai Lab pays -- of its earnings as a dividend. Dr Reddy's Laboratories pays out 11.94% of its earnings as a dividend. Dr Reddy's Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zai Lab quarterly revenues are $102.3M, which are smaller than Dr Reddy's Laboratories quarterly revenues of $956.9M. Zai Lab's net income of -$41.7M is lower than Dr Reddy's Laboratories's net income of $149.8M. Notably, Zai Lab's price-to-earnings ratio is -- while Dr Reddy's Laboratories's PE ratio is 32.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zai Lab is 7.33x versus 3.65x for Dr Reddy's Laboratories. Usually stocks with elevated PS ratios are considered overvalued.

WuXi Biologics (Cayman) has a net margin of -40.75% compared to Zai Lab's net margin of --. Zai Lab's return on equity of -35.53% beat WuXi Biologics (Cayman)'s return on equity of 6.19%.

Zai Lab has a consensus price target of $52.39, signalling upside risk potential of 95.93%. On the other hand WuXi Biologics (Cayman) has an analysts' consensus of -- which suggests that it could fall by --. Given that Zai Lab has higher upside potential than WuXi Biologics (Cayman), analysts believe Zai Lab is more attractive than WuXi Biologics (Cayman).

Zai Lab has a beta of 0.989, which suggesting that the stock is 1.054% less volatile than S&P 500. In comparison WuXi Biologics (Cayman) has a beta of 0.434, suggesting its less volatile than the S&P 500 by 56.625%.

Zai Lab has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. WuXi Biologics (Cayman) offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zai Lab pays -- of its earnings as a dividend. WuXi Biologics (Cayman) pays out -- of its earnings as a dividend.

Zai Lab quarterly revenues are $102.3M, which are larger than WuXi Biologics (Cayman) quarterly revenues of --. Zai Lab's net income of -$41.7M is higher than WuXi Biologics (Cayman)'s net income of --. Notably, Zai Lab's price-to-earnings ratio is -- while WuXi Biologics (Cayman)'s PE ratio is 26.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zai Lab is 7.33x versus 3.95x for WuXi Biologics (Cayman). Usually stocks with elevated PS ratios are considered overvalued.

111 has a net margin of -40.75% compared to Zai Lab's net margin of -0.48%. Zai Lab's return on equity of -35.53% beat 111's return on equity of -89.07%.

Zai Lab has a consensus price target of $52.39, signalling upside risk potential of 95.93%. On the other hand 111 has an analysts' consensus of -- which suggests that it could grow by 582.29%. Given that 111 has higher upside potential than Zai Lab, analysts believe 111 is more attractive than Zai Lab.

Zai Lab has a beta of 0.989, which suggesting that the stock is 1.054% less volatile than S&P 500. In comparison 111 has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.65%.

Zai Lab has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. 111 offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zai Lab pays -- of its earnings as a dividend. 111 pays out -- of its earnings as a dividend.

Zai Lab quarterly revenues are $102.3M, which are smaller than 111 quarterly revenues of $502.9M. Zai Lab's net income of -$41.7M is lower than 111's net income of -$2.4M. Notably, Zai Lab's price-to-earnings ratio is -- while 111's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zai Lab is 7.33x versus 0.04x for 111. Usually stocks with elevated PS ratios are considered overvalued.